U.S., Nov. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07914556) titled 'Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers' on Oct. 19.
Brief Summary: To assess safety and tolerability at increasing dose levels of 6MW5311 in successive cohorts of participants with MM, AML and CMML in order to estimate the maximum tolerated dose (MTD) and select the recommended Phase 2 dose (RP2D) or the recommended expansion dose (RED).
Study Start Date: Sept. 16
Study Type: INTERVENTIONAL
Condition:
AML
Multiple Myeloma
CMML
Intervention:
BIOLOGICAL: 6MW5311
A bispecific T cell engager (TCE) antibody: bivalent binding to LILRB4 on tumor cells and monovalent binding to CD3 on T cells.
Re...